Access audited financial statements, management discussion and analysis, and statutory reports for each financial year.
Financial results are reported quarterly in the format 1QFY26, 2QFY26, 3QFY26, and 4QFY26 in accordance with SEBI listing obligations and BSE/NSE disclosure requirements.
Revenue of ₹469 crore, up 43% year on year — a record quarter. EBITDA of ₹139 crore at a 30% margin, up 42%. Profit after tax of ₹101 crore, up 115%, at a 22% margin.
Metric | FY2024 | FY2025 | FY2026 | Change (YoY) |
|---|---|---|---|---|
| Revenue (₹ crore) | 1,146 | 1,310 | 1,549 | +18% |
| Gross margin | — | 69% | 70% | +100 bps |
| EBITDA (₹ crore) | 237 | 343 | 445 | +30% |
| EBITDA margin | ~21% | 26% | 29% | +300 bps |
| Profit after tax (₹ crore) | 32 | 78 | 243 | +211% |
| Adjusted PAT (₹ crore) | — | 99 | 232 | +135% |
| Adjusted ROCE | 9.3% | 15.0% | 17.4% | +240 bps |
| Net debt / EBITDA | 5.8× | 1.6× | 1.4× | Improved |
| Capex (₹ crore) | 172 | 216 | 361 | +67% |
Figures above reflect results as reported for the periods shown and are updated each reporting cycle — refer to the latest quarterly filing on NSE/BSE for current-period figures.
Segment | Revenue (₹ crore) | Growth (YoY) |
|---|---|---|
| Active Pharmaceutical Ingredients | 985 gross, including captive supply to formulations (769 external) | +16–17% |
| Formulations | 618 | +30% |
| Biologics | 150 | ~+100% |
| Other | 12 | — |
Geography | Revenue (₹ crore) |
|---|---|
| Europe | 223 (crossed ₹200 crore for the first time; approximately doubled year on year) |
| Rest of world | 123 |
| United States | 80 |
| India | 72 |
| Licensing | 13 |
Quarterly results are published on the NSE and BSE stock exchange platforms within 45 days of each quarter end, in compliance with SEBI (LODR) Regulations, 2015.
For the most current quarterly results and financial disclosures:
View on NSEView statutory annual return
Explore our annual return
View quarterly and annual financial results
View financial statements of material subsidiaries
View investor presentations
View stock exchange disclosures
View Business Responsibility and Sustainability Report
View statutory newspaper publications
View Qualified Institutional Placement details
For queries & grievances
Company Secretary & Compliance Officer
#12-6-214/A1,
Hyderabad Road,
Raichur – 584 135,
Karnataka, India.
CIN No.
L85110KA1987PLC008739
